Methylated DAPK and APC promoter DNA detection in peripheral blood is significantly associated with apparent residual tumor and outcome

Journal of Cancer Research and Clinical Oncology

Volumn 135, Issue 9, 2009, Pages 1231-1237

  Hoffmann, Andreas Claudius ^a,d   Vallböhmer, Daniel ^b   Prenzel, Klaus ^b   Metzger, Ralf ^b   Heitmann, Michaela ^b   Neiss, Susanne ^b   Ling, Fredericke ^b   Hölscher, Arnulf H ^b   Schneider, Paul M ^c   Brabender, Jan ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

APC; DAPK; Methylation; Outcome; Peripheral blood; Residual tumor category

Indexed keywords

ANTINEOPLASTIC AGENT; APC PROTEIN; DEATH ASSOCIATED PROTEIN KINASE; DNA;

ADULT; ARTICLE; BLOOD; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA EXTRACTION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFORMATION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; METHYLATION; OUTCOME ASSESSMENT; PATHOLOGY; PLASMA; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; ROC CURVE; SURGICAL TECHNIQUE; SURVIVOR;

ADENOMATOUS POLYPOSIS COLI; APOPTOSIS REGULATORY PROTEINS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; DNA METHYLATION; DNA, NEOPLASM; ESOPHAGEAL NEOPLASMS; HUMANS; MULTIVARIATE ANALYSIS; NEOPLASM, RESIDUAL; PROGNOSIS; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROC CURVE; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 68649085640     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-009-0564-x     Document Type: Article

References (30)

1. SB Baylin JG Herman 2000 DNA hypermethylation in tumorigenesis: epigenetics joins genetics Trends Genet 16 168 174 10.1016/S0168-9525(99)01971-X (Pubitemid 30169152)
2. E Bollschweiler E Wolfgarten C Gutschow AH Holscher 2001 Demographic variations in the rising incidence of esophageal adenocarcinoma in white males Cancer 92 549 555 10.1002/1097-0142(20010801)92:3<549::AID-CNCR1354>3.0. CO;2-L (Pubitemid 32735190)
3. W Doerfler B Weisshaar A Hoeveler D Knebel U Muller P Dobrzanski 1988 Promoter inhibition by DNA methylation: a reversible signal Gene 74 129 133 10.1016/0378-1119(88)90268-5 (Pubitemid 19069361)
4. M Esteller 2008 Epigenetics in cancer N Engl J Med 358 1148 1159 10.1056/NEJMra072067
5. RF Heitmiller 2001 Epidemiology, diagnosis, and staging of esophageal cancer Cancer Treat Res 105 375 386
6. AC Hoffmann U Warnecke-Eberz T Luebke K Prenzel R Metzger M Heitmann 2007 Survivin mRNA in peripheral blood is frequently detected and significantly decreased following resection of gastrointestinal cancers J Surg Oncol 95 51 54 10.1002/jso.20630 (Pubitemid 46122718)
7. Holscher AH, Vallbohmer D (2007) Surgical treatment of esophageal tumors including local ablation. Zentralbl Chir 132:W18-W36 (quiz W37-W38). doi: 10.1055/s-2007-960626
8. JP Issa SB Baylin JG Herman 1997 DNA methylation changes in hematologic malignancies: biologic and clinical implications Leukemia 11 Suppl 1 S7 S11
9. A Jemal R Siegel E Ward Y Hao J Xu T Murray 2008 Cancer statistics, 2008 CA Cancer J Clin 58 71 96 10.3322/CA.2007.0010
10. T Junginger P Hermanek K Oberholzer H Schmidberger 2006 Rectal carcinoma: is too much neoadjuvant therapy performed? Proposals for a more selective MRI based indication Zentralbl Chir 131 275 284
11. K Kawakami J Brabender RV Lord S Groshen BD Greenwald MJ Krasna 2000 Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma J Natl Cancer Inst 92 1805 1811 10.1093/jnci/92.22.1805
12. D Kuester AA Dar CC Moskaluk S Krueger F Meyer R Hartig 2007 Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression Neoplasia 9 236 245 10.1593/neo.06802 (Pubitemid 46457240)
13. F Lordick K Ott A Novotny C Schuhmacher JR Siewert 2007 R1 resection in the surgery of upper gastrointestinal tumors: relevance and therapeutic consequences Chirurg 78 792 801 10.1007/s00104-007-1381-x
14. JA Ludwig JN Weinstein 2005 Biomarkers in cancer staging, prognosis and treatment selection Nat Rev Cancer 5 845 856 10.1038/nrc1739 (Pubitemid 41746029)
15. G Mathew GG Jamieson 1997 Neoadjuvant therapy for oesophageal cancer Br J Surg 84 1185 1187 10.1002/bjs.1800840902 (Pubitemid 27400261)
16. M Moehler CC Schimanski I Gockel T Junginger PR Galle 2004 (Neo)adjuvant strategies of advanced gastric carcinoma: time for a change? Dig Dis 22 345 350 10.1159/000083597 (Pubitemid 41213051)
17. AN Reddy WW Jiang M Kim N Benoit R Taylor J Clinger 2003 Death-associated protein kinase promoter hypermethylation in normal human lymphocytes Cancer Res 63 7694 7698
18. PR Rohatgi SG Swisher AM Correa TT Wu Z Liao GL Walsh 2005 Comparison of clinical stage, therapy response, and patient outcome between squamous cell carcinoma and adenocarcinoma of the esophagus Int J Gastrointest Cancer 36 69 76 10.1385/IJGC:36:2:69
19. F Sato SJ Meltzer 2006 CpG island hypermethylation in progression of esophageal and gastric cancer Cancer 106 483 493 10.1002/cncr.21657 (Pubitemid 43157610)
20. HU Schildhaus I Krockel H Lippert P Malfertheiner A Roessner R Schneider-Stock 2005 Promoter hypermethylation of p16INK4a, E-cadherin, O6-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach Int J Oncol 26 1493 1500
21. PM Schneider SE Baldus R Metzger M Kocher R Bongartz E Bollschweiler 2005 Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification Ann Surg 242 684 692 10.1097/01.sla.0000186170.38348.7b (Pubitemid 41567124)
22. S Schneider K Uchida J Brabender SE Baldus J Yochim KD Danenberg 2005 Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer J Am Coll Surg 200 336 344 10.1016/j.jamcollsurg.2004.10.035 (Pubitemid 40298967)
23. JR Siewert K Ott 2007 Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol 17 38 44 10.1016/j.semradonc.2006.09.007 (Pubitemid 44918361)
24. LH Sobin ID Fleming 1997 TNM classification of malignant tumors, fifth edition Union Internationale Contre le Cancer and the American Joint Committee on Cancer Cancer 80 1803 1804 10.1002/(SICI)1097-0142(19971101)80:9<1803:: AID-CNCR16>3.0.CO;2-9 (Pubitemid 27475940)
25. SG Swisher EC Holmes KK Hunt JE Doty MJ Zinner DW McFadden 1996 The role of neoadjuvant therapy in surgically resectable esophageal cancer Arch Surg 131 819 824 discussion 824-5
26. SG Urba MB Orringer A Turrisi M Iannettoni A Forastiere M Strawderman 2001 Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma J Clin Oncol 19 305 313
27. D Vallbohmer HJ Lenz 2006 Predictive and prognostic molecular markers in outcome of esophageal cancer Dis Esophagus 19 425 432 10.1111/j.1442-2050.2006. 00622.x (Pubitemid 44644677)
28. D Vallbohmer J Brabender D Yang PM Schneider R Metzger KD Danenberg 2006 DNA methyltransferases messenger RNA expression and aberrant methylation of CpG islands in non-small-cell lung cancer: association and prognostic value Clin Lung Cancer 8 39 44 10.3816/CLC.2006.n.031
29. U Warnecke-Eberz R Metzger F Miyazono SE Baldus S Neiss J Brabender 2004 High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer Clin Cancer Res 10 3794 3799 10.1158/1078-0432.CCR-03-0079 (Pubitemid 38697614)
30. R Wong R Malthaner 2000 Esophageal cancer: a systematic review Curr Probl Cancer 24 297 373 10.1016/S0147-0272(00)80002-1